Richard James Ivey

US Patent:

7645573, Jan 12, 2010

Filed:

Nov 12, 2003

Appl. No.:

10/704666

Inventors:

Richard M. Ivey - Parkton MD, US
Richard L. Moore - Glenville PA, US
Michael L. Towns - Timonium MD, US
Nicholas Bachur, Jr. - Monkton MD, US
Robert W. Rosenstein - Ellicott City MD, US
Paul E. Goldenbaum - Hampstead MD, US
Song Shi - Reisterstown MD, US
Donald Copertino - Catonsville MD, US
James Garrett - Baltimore MD, US
Gregory Tice - Lutherville MD, US

Assignee:

Becton, Dickinson and Company - Franklin Lakes NJ

International Classification:

C12Q 1/68
C12P 19/34

US Classification:

435 6, 435 912

Abstract:

The early prediction or diagnosis of sepsis advantageously allows for clinical intervention before the disease rapidly progresses beyond initial stages to the more severe stages, such as severe sepsis or septic shock, which are associated with high mortality. Early prediction or diagnosis is accomplished using a molecular diagnostics approach, involving comparing an individual's profile of biomarker expression to profiles obtained from one or more control, or reference, populations, which may include a population who develops sepsis. Recognition of features in the individual's biomarker profile that are characteristic of the onset of sepsis allows a clinician to diagnose the onset of sepsis from a bodily fluid isolated at the individual at a single point in time. The necessity of monitoring the patient over a period of time is, therefore, avoided, advantageously allowing clinical intervention before the onset of serious symptoms. Further, because the biomarker expression is assayed for its profile, identification of the particular biomarkers is unnecessary.

US Patent:

7645613, Jan 12, 2010

Filed:

Dec 28, 2006

Appl. No.:

11/647688

Inventors:

Richard M. Ivey - Parkton MD, US
Richard L. Moore - Glenville PA, US
Michael L. Towns - Timonium MD, US
Gary Siuzdak - San Diego CA, US
Elizabeth J. Want - San Diego CA, US
Zhouxin Shen - San Diego CA, US
Nicholas Bachur, Jr. - Monkton MD, US
Robert W. Rosenstein - Ellicott City MD, US
James G. Nadeau - Ellicott City MD, US
Paul E. Goldenbaum - Hampstead MD, US
Song Shi - Reisterstown MD, US
Donald Copertino - Catonsville MD, US
James Garrett - Baltimore MD, US
Gregory Tice - Lutherville MD, US

Assignee:

Becton, Dickinson and Company - Franklin Lakes NJ

International Classification:

G01N 24/00

US Classification:

436173, 436 89

Abstract:

Mass spectrometry techniques for determining the status of sepsis in an individual are provided. A biomarker profile resolved from a biological sample, taken from the individual, using a mass spectrometry technique is compared to a reference biomarker profile. A single such comparison classifies the individual as belonging to or not belonging to a reference population. The individual's biomarker profile and the reference biomarker profile comprise a plurality of ions each having a mass-to-charge ratio of about 100 Daltons to about 1000 Daltons. The plurality of ions can be detected by electrospray ionization mass spectrometry in positive mode. The comparison uses a decision rule, such as a classification tree, that determines the status of sepsis in the individual without requiring knowledge of the identity of the biomarkers in the biomarker profile from the individual and without requiring knowledge of the identity of the biomarkers in the reference biomarker profile.

US Patent:

7776522, Aug 17, 2010

Filed:

Apr 24, 2008

Appl. No.:

12/108550

Inventors:

Richard Ivey - Parkton MD, US
Stephen J. Lovell - Lutherville MD, US
Robert Rosenstein - Elicott City MD, US
Thomas Gentle - St. Michael MN, US
Song Shi - Reisterstown MD, US

Assignee:

Becton, Dickinson and Company - Franklin Lakes NJ

International Classification:

C12Q 1/68

US Classification:

435 5

Abstract:

Methods for diagnosis of HPV infection in a subject are provided. HPV infection in a subject can be determined by generating mass profile data for a biological sample from the subject and correlating the mass profile data with reference mass profiles to detect the presence or absence, and/or quantity of at least one biomarker associated with HPV infection. Methods for detecting at least one biomarker associated with HPV infection in a biological sample are also provided.

US Patent:

20040096917, May 20, 2004

Filed:

Nov 12, 2003

Appl. No.:

10/704899

Inventors:

Richard Ivey - Parkton MD, US
Thomas Gentle - Red Lion PA, US
Richard Moore - Glenville PA, US
Michael Towns - Timonium MD, US
Nicholas Bachur - Monkton MD, US
Robert Rosenstein - Ellicott City MD, US
James Nadeau - Ellicott City MD, US
Paul Goldenbaum - Hampstead MD, US
Song Shi - Reisterstown MD, US
Donald Copertino - Catonsville MD, US
James Garrett - Baltimore MD, US
Gregory Tice - Lutherville MD, US

Assignee:

Becton, Dickinson and Company - Franklin Lakes NJ

International Classification:

G01N033/554
G01N033/569

US Classification:

435/007320

Abstract:

The early prediction or diagnosis of sepsis advantageously allows for clinical intervention before the disease rapidly progresses beyond initial stages to the more severe stages, such as severe sepsis or septic shock, which are associated with high mortality. Early prediction or diagnosis is accomplished by comparing an individual's profile of biomarker expression to profiles obtained from one or more control, or reference, populations, which may include a population that develops sepsis. Recognition of features in the individual's biomarker profile that are characteristic of the onset of sepsis allows a clinician to diagnose the onset of sepsis from a bodily fluid isolated from the individual at a single point in time. The necessity of monitoring the patient over a period of time is, therefore, avoided, advantageously allowing clinical intervention before the onset of serious symptoms of sepsis. Further, because the biomarker expression is assayed for its profile, identification of the particular biomarkers is unnecessary. The comparison of an individual's biomarker profile to biomarker profiles of appropriate reference populations likewise can be used to diagnose SIRS in the individual.

US Patent:

20040097460, May 20, 2004

Filed:

Nov 12, 2003

Appl. No.:

10/704661

Inventors:

Richard Ivey - Parkton MD, US
Thomas Gentle - Red Lion PA, US
Richard Moore - Glenville PA, US
Michael Towns - Timonium MD, US
Nicholas Bachur - Monkton MD, US
Robert Rosenstein - Ellicott City MD, US
Paul Goldenbaum - Hampstead MD, US
Song Shi - Reisterstown MD, US
Donald Copertino - Catonsville MD, US
James Garrett - Baltimore MD, US
Gregory Tice - Lutherville MD, US

Assignee:

Becton, Dickinson and Company - Franklin Lakes NJ

International Classification:

A61K048/00
C12Q001/68

US Classification:

514/044000, 435/006000

Abstract:

The early prediction or diagnosis of sepsis advantageously allows for clinical intervention before the disease rapidly progresses beyond initial stages to the more severe stages, such as severe sepsis or septic shock, which are associated with high mortality. Early prediction or diagnosis is accomplished using a molecular diagnostics approach, involving comparing an individual's profile of biomarker expression to profiles obtained from one or more control, or reference, populations, which may include a population that develops sepsis. Recognition of features in the individual's biomarker profile that are characteristic of the onset of sepsis allows a clinician to diagnose the onset of sepsis from a bodily fluid isolated at the individual at a single point in time. The necessity of monitoring the patient over a period of time is, therefore, avoided, advantageously allowing clinical intervention before the onset of serious symptoms of sepsis. Further, because the biomarker expression is assayed for its profile, identification of the particular biomarkers is unnecessary. The comparison of an individual's biomarker profile to biomarker profiles of appropriate reference populations likewise can be used to diagnose SIRS in the individual.

US Patent:

20040157242, Aug 12, 2004

Filed:

Nov 12, 2003

Appl. No.:

10/704758

Inventors:

Richard Ivey - Parkton MD, US
Thomas Gentle - Red Lion PA, US
Richard Moore - Glenville PA, US
Michael Towns - Timonium MD, US
Nicholas Bachur - Monkton MD, US
Robert Rosenstein - Ellicott City MD, US
James Nadeau - Ellicott City MD, US
Paul Goldenbaum - Hampstead MD, US
Song Shi - Reisterstown MD, US
Donald Copertino - Catonsville MD, US
James Garrett - Baltimore MD, US
Gregory Tice - Lutherville MD, US
Gary Siuzdak - San Diego CA, US
Elizabeth Want - San Diego CA, US
Zhouxin Shen - San Diego CA, US

Assignee:

Becton, Dickinson and Company - Franklin Lakes NJ

International Classification:

C12Q001/68
G01N033/53

US Classification:

435/006000, 435/007100

Abstract:

The early prediction or diagnosis of sepsis advantageously allows for clinical intervention before the disease rapidly progresses beyond initial stages to the more severe stages, such as severe sepsis or septic shock, which are associated with high mortality. Early prediction or diagnosis is accomplished by comparing an individual's profile of biomarker expression to profiles obtained from one or more control, or reference, populations, which may include a population who develops sepsis. Recognition of features in the individual's biomarker profile that are characteristic of the onset of sepsis allows a clinician to diagnose the onset of sepsis from a bodily fluid isolated at the individual at a single point in time. The necessity of monitoring the patient over a period of time is, therefore, avoided, advantageously allowing clinical intervention before the onset of serious symptoms. Further, because the biomarker expression is assayed for its profile, identification of the particular biomarkers is unnecessary. The comparison of an individual's biomarker profile to biomarker profiles of appropriate reference populations likewise can be used to diagnose SIRS in the individual.

US Patent:

20080050829, Feb 28, 2008

Filed:

Dec 28, 2006

Appl. No.:

11/647689

Inventors:

Richard Ivey - Parkton MD, US
Thomas Gentle - Red Lion PA, US
Richard Moore - Glenville PA, US
Michael Towns - Timonium MD, US
Nicholas Bachur - Monkton MD, US
Robert Rosenstein - Ellicott City MD, US
James Nadeau - Ellicott City MD, US
Paul Goldenbaum - Hampstead MD, US
Song Shi - Reisterstown MD, US
Donald Copertino - Catonsville MD, US
James Garrett - Baltimore MD, US
Gregory Tice - Lutherville MD, US
Gary Siuzdak - San Diego CA, US
Elizabeth Want - San Diego CA, US
Zhouxin Shen - San Diego CA, US

International Classification:

G01N 33/00
C12N 1/02

US Classification:

436063000, 435029000

Abstract:

Mass spectrometry techniques for determining the status of sepsis in an individual are provided. A biomarker profile resolved from a biological sample, taken from the individual, using a mass spectrometry technique is compared to a reference biomarker profile. A single such comparison classifies the individual as belonging to or not belonging to a reference population. The individual's biomarker profile and the reference biomarker profile comprise a plurality of ions each having a mass-to-charge ratio of about 100 Daltons to about 1000 Daltons. The plurality of ions can be detected by electrospray ionization mass spectrometry in positive mode. The comparison uses a decision rule, such as a classification tree, that determines the status of sepsis in the individual without requiring knowledge of the identity of the biomarkers in the biomarker profile from the individual and without requiring knowledge of the identity of the biomarkers in the reference biomarker profile.

US Patent:

20080138832, Jun 12, 2008

Filed:

Sep 25, 2007

Appl. No.:

11/904282

Inventors:

Richard M. Ivey - Parkton MD, US
Thomas M. Gentle - Red Lion PA, US
Richard L. Moore - Glenville PA, US
Michael L. Towns - Timonium MD, US
Nicholas Bachur - Monkton MD, US
Robert W. Rosenstein - Ellicott City MD, US
James G. Nadeau - Ellicott City MD, US
Paul E. Goldenbaum - Hampstead MD, US
Song Shi - Reisterstown MD, US
Donald Copertino - Catonsville MD, US
James Garrett - Baltimore MD, US
Gregory Tice - Lutherville MD, US

Assignee:

Becton, Dickinson and Company - Franklin Lakes NJ

International Classification:

G01N 33/53
C12Q 1/02
G01N 33/00

US Classification:

435 71, 435 29, 436 63

Abstract:

The early prediction or diagnosis of sepsis advantageously allows for clinical intervention before the disease rapidly progresses beyond initial stages to the more severe stages, such as severe sepsis or septic shock, which are associated with high mortality. Early prediction or diagnosis is accomplished by comparing an individual's profile of biomarker expression to profiles obtained from one or more control, or reference, populations, which may include a population that develops sepsis. Recognition of features in the individual's biomarker profile that are characteristic of the onset of sepsis allows a clinician to diagnose the onset of sepsis from a bodily fluid isolated from the individual at a single point in time. The necessity of monitoring the patient over a period of time is, therefore, avoided, advantageously allowing clinical intervention before the onset of serious symptoms of sepsis. Further, because the biomarker expression is assayed for its profile, identification of the particular biomarkers is unnecessary. The comparison of an individual's biomarker profile to biomarker profiles of appropriate reference populations likewise can be used to diagnose SIRS in the individual.